T Cell News and Research

Latest T Cell News and Research

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Researchers discover new signaling pathway for cell development

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

24 Sep 2010

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Preclinical data of a novel therapy designed to treat drug-resistant hypertension (high blood pressure) was presented Tuesday, September 21st, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Conference in Washington, DC, by Christopher D. Owens, MD, MSc, Assistant Professor in Residence, Division of Vascular and Endovascular Surgery, University of California, San Francisco.

24 Sep 2010

Scientists uncover alternative source for damage associated with MS

Scientists have uncovered an alternative source for some of the damage associated with multiple sclerosis, an incurable neuroinflammatory disorder. The research, published online by Cell Press on September 23rd in the journal Immunity, reveals a direct interaction between immune cells and neurons that plays a significant role in neuronal injury and may respond to therapeutic intervention.

24 Sep 2010

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Cerus Corporation announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company's pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

24 Sep 2010

Researchers discover molecular signature to predict TB infection

Dallas scientists recently discovered a molecular signature in the blood of patients with tuberculosis (TB) that may explain why some people develop an active TB infection, while others exposed to the bacteria which causes the dangerous respiratory virus do not.

24 Sep 2010

New website offers real-life case studies and immunology breakthroughs on HIV

Amid a devastating HIV epidemic, some South African pediatricians treat as many as 100 children per day. With such overwhelming case loads, the physicians have little time to review the information they were offered in medical school on the topic of immunology. Recognizing the potential value of an understanding of up-to-date immunology in the treatment of HIV, immunologist Clive Gray developed Immunopaedia, a Web site that quickly and efficiently gives doctors a working knowledge of immunology through real-life case studies and news of immunology breakthroughs.

24 Sep 2010

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

NeoStem, Inc. an international biopharmaceutical company with operations in the U.S. and China and Progenitor Cell Therapy, LLC a privately held cell therapy company that serves the cell therapy industry from licensed, state-of-the art cell therapy manufacturing facilities in New Jersey and California today jointly announced the signing of a definitive merger agreement whereby NeoStem will acquire Progenitor Cell Therapy.

24 Sep 2010

Immune-mediated disturbances of neurons contribute to MS: Research

Researchers in Germany have gained new insight into how the immune system causes damage associated with multiple sclerosis (MS), an incurable neuroinflammatory disorder.

24 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

Researchers report MALAT1 gene regulates pre-mRNA splicing in cancer

Researchers report this month that MALAT1, a long non-coding RNA that is implicated in certain cancers, regulates pre-mRNA splicing a critical step in the earliest stage of protein production. Their study appears in the journal Molecular Cell.

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

BioCision launches CryoPrep System for cell freezing procedures

BioCision LLC, the CoolPrep company, announced today that it has expanded its line of innovative benchtop sample handling tools with the launch of the CryoPrep System, a modular complete solution for cell freezing procedures.

23 Sep 2010

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.

23 Sep 2010

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.

23 Sep 2010

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST.

23 Sep 2010

T Cell News and Research

Latest T Cell News and Research

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

Researchers discover new signaling pathway for cell development

Preclinical data of novel drug-resistant hypertension therapy presented at TCT 2010

Scientists uncover alternative source for damage associated with MS

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Researchers discover molecular signature to predict TB infection

New website offers real-life case studies and immunology breakthroughs on HIV

NeoStem signs merger agreement to acquire Progenitor Cell Therapy

Immune-mediated disturbances of neurons contribute to MS: Research

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Researchers report MALAT1 gene regulates pre-mRNA splicing in cancer

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Tolerx presents otelixizumab preclinical research at 46th EASD

BioCision launches CryoPrep System for cell freezing procedures

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

Raltegravir could be valid target against all Herpesviridae

Athersys presents MultiStem phase I study results at TCT Conference

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in